Unfortunately, mTOR inhibitors do not appear to improve PFS relative to standard chemotherapy regimens or provide OS benefit in TSC1/TSC2 mutated malignant PEComas (38, 73). The gene discussed is TSC2; the disease is neoplasm with perivascular epithelioid cell differentiation.